 | - 4 to be charged in record ecstasy case, PG decides
(Aug 06, 2007)
- Deadlock at Rosh Pinah
(Aug 06, 2007)
- Computer theft ring cracked
(Aug 06, 2007)
- Our Nicolas Sarkozy must please stand up!
(May 17, 2007)
- Electricity in Namibia - Quo Vadis?
(May 17, 2007)
- Political Perspective
(May 17, 2007)
- Attacks On Media Persist
(May 17, 2007)
- 'Not guilty', says family shooting suspect Endjala
(May 16, 2007)
- Racist backlash angers City Lutheran pastor
(May 16, 2007)
- Episode two in rugby’s Who’s the Boss?
(May 15, 2007)
|
|  |
 | - All topics
- Buisiness and Economy (May 10, 2007)
- Computer Games (May 11, 2007)
- Entertainment Music, Movies .... (Aug 06, 2007)
- Enviroment (May 17, 2007)
- General Health (May 16, 2007)
- International News (May 08, 2007)
- Namibia in the News (Aug 06, 2007)
- Namibian Elections 2004 (May 16, 2007)
- PostNuke (May 16, 2007)
- Religion (May 13, 2007)
- Science and Technology (May 16, 2007)
- Sport (May 17, 2007)
- Travel, Tourism (May 15, 2007)
|
|  |
|
|
 | | Posted by Admin on Wednesday, May 02, 2007 - 07:03 PM |
|  |
 |  | Early use of Bayer's multiple-sclerosis (MS) drug Betaseron can significantly delay permanent disability for patients with MS, the German drugs and chemicals company said on Tuesday. MS is a degenerative disease of the nervous system that can lead to muscle weakness, blurred vision and disability. About 2.5 million people are estimated to suffer from the disease.
Bayer said new data from a study showed immediate use of Betaseron in patients with the first signs of multiple sclerosis can cut the risk of permanent neurological damage by 40 percent over three years compared with delayed treatment. "This is a truly novel finding that has not yet been demonstrated for any other immunomodulatory MS treatment," said Dr Mark Freedman of the University of Ottawa, who led the study. The results underscored the urgent need to treat patients early rather than waiting for further signs of the disease to develop, Freedman said in a statement. The BENEFIT study -- Betaseron in newly emerging multiple sclerosis for initial treatment -- involved 468 patients and was presented at the American Academy of Neurology in Boston on Tuesday. | |
|  |
|
|
|
|